What Does The Future Hold For Cohance Lifesciences Limited (NSE:COHANCE)? These Analysts Have Been Cutting Their Estimates

One thing we could say about the analysts on Cohance Lifesciences Limited (NSE:COHANCE) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the downgrade, the most recent consensus for Cohance Lifesciences from its eight analysts is for revenues of ₹26b in 2026 which, if met, would be a substantial 109% increase on its sales over the past 12 months. Before the latest update, the analysts were foreseeing ₹30b of revenue in 2026. It looks like forecasts have become a fair bit less optimistic on Cohance Lifesciences, given the substantial drop in revenue estimates.

View our latest analysis for Cohance Lifesciences

We'd point out that there was no major changes to their price target of ₹1,154, suggesting the latest estimates were not enough to shift their view on the value of the business.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Cohance Lifesciences' rate of growth is expected to accelerate meaningfully, with the forecast 3x annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 2.9% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 11% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Cohance Lifesciences to grow faster than the wider industry.

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for Cohance Lifesciences this year. They're also forecasting more rapid revenue growth than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Cohance Lifesciences going forwards.

Hungry for more information? We have estimates for Cohance Lifesciences from its eight analysts out until 2028, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.